130 related articles for article (PubMed ID: 27086111)
1. Pharmacokinetic properties of tandem d-peptides designed for treatment of Alzheimer's disease.
Leithold LH; Jiang N; Post J; Niemietz N; Schartmann E; Ziehm T; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Eur J Pharm Sci; 2016 Jun; 89():31-8. PubMed ID: 27086111
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers.
Leithold LH; Jiang N; Post J; Ziehm T; Schartmann E; Kutzsche J; Shah NJ; Breitkreutz J; Langen KJ; Willuweit A; Willbold D
Pharm Res; 2016 Feb; 33(2):328-36. PubMed ID: 26381279
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease.
Jiang N; Leithold LH; Post J; Ziehm T; Mauler J; Gremer L; Cremer M; Schartmann E; Shah NJ; Kutzsche J; Langen KJ; Breitkreutz J; Willbold D; Willuweit A
PLoS One; 2015; 10(6):e0128553. PubMed ID: 26046986
[TBL] [Abstract][Full Text] [Related]
4. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease.
Schartmann E; Schemmert S; Ziehm T; Leithold LHE; Jiang N; Tusche M; Joni Shah N; Langen KJ; Kutzsche J; Willbold D; Willuweit A
Eur J Pharm Sci; 2018 Mar; 114():93-102. PubMed ID: 29225107
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Efficacies of the Linear and the Cyclic Version of an All-d-Enantiomeric Peptide Developed for the Treatment of Alzheimer's Disease.
Schemmert S; Camargo LC; Honold D; Gering I; Kutzsche J; Willuweit A; Willbold D
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207233
[TBL] [Abstract][Full Text] [Related]
6. Surprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs.
Elfgen A; Santiago-Schübel B; Gremer L; Kutzsche J; Willbold D
Eur J Pharm Sci; 2017 Sep; 107():203-207. PubMed ID: 28711713
[TBL] [Abstract][Full Text] [Related]
7. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid.
Elfgen A; Santiago-Schübel B; Hupert M; Schemmert S; Schartmann E; Tusche M; Gering I; Zafiu C; Kutzsche J
Eur J Pharm Sci; 2021 Jan; 156():105581. PubMed ID: 33035662
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in vivo staining characteristics of small, fluorescent, Abeta42-binding D-enantiomeric peptides in transgenic AD mouse models.
van Groen T; Kadish I; Wiesehan K; Funke SA; Willbold D
ChemMedChem; 2009 Feb; 4(2):276-82. PubMed ID: 19072935
[TBL] [Abstract][Full Text] [Related]
9. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers.
Elfgen A; Hupert M; Bochinsky K; Tusche M; González de San Román Martin E; Gering I; Sacchi S; Pollegioni L; Huesgen PF; Hartmann R; Santiago-Schübel B; Kutzsche J; Willbold D
Sci Rep; 2019 Apr; 9(1):5715. PubMed ID: 30952881
[TBL] [Abstract][Full Text] [Related]
10. Reduction of Alzheimer's disease amyloid plaque load in transgenic mice by D3, A D-enantiomeric peptide identified by mirror image phage display.
van Groen T; Wiesehan K; Funke SA; Kadish I; Nagel-Steger L; Willbold D
ChemMedChem; 2008 Dec; 3(12):1848-52. PubMed ID: 19016284
[No Abstract] [Full Text] [Related]
11. The effects of age on uptake, serum half-life and bioavailability of mouse [D-Leu-4]OB3, a synthetic peptide amide with leptin-like activity, in male C57BL/6J mice.
Lee DW; Leinung MC; Grasso P
Regul Pept; 2008 Oct; 150(1-3):62-5. PubMed ID: 18455249
[TBL] [Abstract][Full Text] [Related]
12. Establishing the relationship between in vitro potency, pharmacokinetic, and pharmacodynamic parameters in a series of orally available, hydroxyethylamine-derived β-secretase inhibitors.
Wood S; Wen PH; Zhang J; Zhu L; Luo Y; Babu-Khan S; Chen K; Pham R; Esmay J; Dineen TA; Kaller MR; Weiss MM; Hitchcock SA; Citron M; Zhong W; Hickman D; Williamson T
J Pharmacol Exp Ther; 2012 Nov; 343(2):460-7. PubMed ID: 22911925
[TBL] [Abstract][Full Text] [Related]
13. Design and evaluation of a 6-mer amyloid-beta protein derived phage display library for molecular targeting of amyloid plaques in Alzheimer's disease: Comparison with two cyclic heptapeptides derived from a randomized phage display library.
Larbanoix L; Burtea C; Ansciaux E; Laurent S; Mahieu I; Vander Elst L; Muller RN
Peptides; 2011 Jun; 32(6):1232-43. PubMed ID: 21575663
[TBL] [Abstract][Full Text] [Related]
14. Stability of oxymethyl-modified coumarinic acid cyclic prodrugs of diastereomeric opioid peptides in biological media from various animal species including human.
Liederer BM; Borchardt RT
J Pharm Sci; 2005 Oct; 94(10):2198-206. PubMed ID: 16136552
[TBL] [Abstract][Full Text] [Related]
15. Assessment of in vitro metabolic stability, plasma protein binding, and pharmacokinetics of E- and Z-guggulsterone in rat.
Chhonker YS; Chandasana H; Mukkavilli R; Prasad YD; Laxman TS; Vangala S; Bhatta RS
Drug Test Anal; 2016 Sep; 8(9):966-75. PubMed ID: 26608935
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice.
Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF
J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020
[TBL] [Abstract][Full Text] [Related]
17. Identification of avidin and streptavidin binding motifs among peptides selected from a synthetic peptide library consisting solely of D-amino acids.
Gissel B; Jensen MR; Gregorius K; Elsner HI; Svendsen I; Mouritsen S
J Pept Sci; 1995; 1(4):217-26. PubMed ID: 9222999
[TBL] [Abstract][Full Text] [Related]
18. Beta-sheet breaker peptide inhibitor of Alzheimer's amyloidogenesis with increased blood-brain barrier permeability and resistance to proteolytic degradation in plasma.
Poduslo JF; Curran GL; Kumar A; Frangione B; Soto C
J Neurobiol; 1999 Jun; 39(3):371-82. PubMed ID: 10363910
[TBL] [Abstract][Full Text] [Related]
19. QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers.
Brener O; Dunkelmann T; Gremer L; van Groen T; Mirecka EA; Kadish I; Willuweit A; Kutzsche J; Jürgens D; Rudolph S; Tusche M; Bongen P; Pietruszka J; Oesterhelt F; Langen KJ; Demuth HU; Janssen A; Hoyer W; Funke SA; Nagel-Steger L; Willbold D
Sci Rep; 2015 Sep; 5():13222. PubMed ID: 26394756
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pharmacokinetic and metabolic profiling among gossypol, apogossypol and apogossypol hexaacetate.
Jia L; Coward LC; Kerstner-Wood CD; Cork RL; Gorman GS; Noker PE; Kitada S; Pellecchia M; Reed JC
Cancer Chemother Pharmacol; 2008 Jan; 61(1):63-73. PubMed ID: 17356822
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
